RT Journal Article
SR Electronic
T1 Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP e003776
DO 10.1136/jitc-2021-003776
VO 10
IS 2
A1 Schöffski, Patrick
A1 Tan, Daniel S W
A1 Martín, Miguel
A1 Ochoa-de-Olza, María
A1 Sarantopoulos, John
A1 Carvajal, Richard D
A1 Kyi, Chrisann
A1 Esaki, Taito
A1 Prawira, Amy
A1 Akerley, Wallace
A1 De Braud, Filippo
A1 Hui, Rina
A1 Zhang, Tian
A1 Soo, Ross A
A1 Maur, Michela
A1 Weickhardt, Andrew
A1 Krauss, Jürgen
A1 Deschler-Baier, Barbara
A1 Lau, Allen
A1 Samant, Tanay S
A1 Longmire, Tyler
A1 Chowdhury, Niladri Roy
A1 Sabatos-Peyton, Catherine A
A1 Patel, Nidhi
A1 Ramesh, Radha
A1 Hu, Tiancen
A1 Carion, Ana
A1 Gusenleitner, Daniel
A1 Yerramilli-Rao, Padmaja
A1 Askoxylakis, Vasileios
A1 Kwak, Eunice L
A1 Hong, David S
YR 2022
UL http://jitc.bmj.com/content/10/2/e003776.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.